← Back to Search

Gene Therapy

FLT190 for Fabry Disease (MARVEL1 Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Freeline Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from screening to 12 weeks post infusion
Awards & highlights

MARVEL1 Trial Summary

This trial looks at a drug for treating a rare disorder in men. It evaluates safety & effectiveness.

Eligible Conditions
  • Fabry Disease
  • Lysosomal Storage Diseases

MARVEL1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from screening to 12 weeks post infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and from screening to 12 weeks post infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of treatment-emergent adverse events (AEs)

MARVEL1 Trial Design

1Treatment groups
Experimental Treatment
Group I: FLT190Experimental Treatment1 Intervention
FLT190 is a recombinant adeno- associated viral (AAV) vector. Administered by a single intravenous infusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FLT190
2020
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Freeline TherapeuticsLead Sponsor
5 Previous Clinical Trials
74 Total Patients Enrolled
1 Trials studying Fabry Disease
3 Patients Enrolled for Fabry Disease
~1 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top